- HOME
- Nippon Shinyaku’s R&D Activities
Nippon Shinyaku’s R&D Activities
We focus our drug discovery research on strategic fields such as urology and hematology, and on the elucidation of the causes of new diseases. By doing so, we are speedily developing original and unique products.
- December 22, 2021
- Zogenix Submission of New Drug Application for ZX008 (Fenfluramine Hydrochloride) in Japan
- December 10, 2021
- Coverage in NHI Drug Price Listing and Launch Date of TADALAFIL Tablets 2.5 mg/5 mg ZA "SIOE"
- November 29, 2021
- Nippon Shinyaku Implements VILTEPSO Managed Access Program
- December 22, 2021
- Zogenix Submission of New Drug Application for ZX008 (Fenfluramine Hydrochloride) in Japan
- December 10, 2021
- Coverage in NHI Drug Price Listing and Launch Date of TADALAFIL Tablets 2.5 mg/5 mg ZA "SIOE"
- November 29, 2021
- Nippon Shinyaku Implements VILTEPSO Managed Access Program
- November 25, 2021
- Addition of Viltepso to the List of Injection Drugs That Physicians Providing Health Insurance Treatment Can Administer
- November 10, 2021
- Nippon Shinyaku enter into an Option Agreement for DYN101 in Japan
- September 22, 2021
- VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting
- September 17, 2021
- VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference
- July 01, 2021
- VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference
- November 25, 2020
- (Media)Nippon Shinyaku Submitted Additional Application of Uptravi for "Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”
- August 13, 2020
- VILTEPSO (viltolarsen) Now Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy
- May 12, 2020
- First Patient Enrolled in Phase 3 Trial of Viltolarsen (NS-065/NCNP-01), an Investigational Antisense Oligonucleotide
- November 06, 2019
- (Media)Designation of Oligonucleotides NS-065/NCNP-01(viltolarsen) Subjected to Conditional Early Approval System
- October 07, 2019
- (Media)Morpholino Oligonucleotide NS-065/NCNP-01 (viltolarsen), Presentation on results of an additional analysis of Phase I/II study in Japan
- October 07, 2019
- (Media)Morpholino Oligonucleotide NS-065/NCNP-01 (viltolarsen) Presentation of Phase II Study in the US
- October 02, 2019
- (Media)U.S. FDA Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen)
- September 26, 2019
- (Media)Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in Japan
- September 04, 2019
- (Media)Launch of Defitelio® injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease)
- August 22, 2019
- (Media)NS-065/NCNP-01 (viltolarsen) under development, granted Orphan Drug Designation by MHLW
- October 17, 2018
- New Drug Application Filed for defibrotide sodium
- October 03, 2018
- NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase I/II study in Japan
- October 03, 2018
- NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase II study in US/Canada
- September 19, 2018
- Orphan drug designation granted to NS-73
- August 29, 2018
- Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody “GAZYVA®"
- August 10, 2018
- Presentations on NS-065/ NCNP-01 at the 23rd International Annual Congress of the World Muscle Society
- June 28, 2018
- Presentation of top line results of Phase I/II study of NS-065/NCNP-01 in Japan, for Duchenne muscular dystrophy
- June 28, 2018
- Presentation of top line results of US/Canada Phase II study of NS-065/NCNP-01, for Duchenne muscular dystrophy
Therapeutic Areas
We are focusing our R&D on these five priority.